Several less well-known disorders share some characteristics with CML. These rare CML-like disorders are distinct entities that require specific diagnostic and treatment considerations. Atypical CML, ...
To evaluate the role of Hh signalling in CML, Reya and colleagues developed mice that lacked expression of smoothened (SMO), the transmembrane protein that transmits Hh signals, in haematopoietic ...
Medications for CML directly destroy cancer cells or help the body’s immune system attack cancer cells to prevent them from growing. Medications may not cure CML, so people may need to continue taking ...
Study design and treatment strategy have been published previously. 3, 8 In brief, newly diagnosed CML patients in chronic phase (CP) were randomized into a 5-arm study comparing IM400 mg/day vs IM400 ...
Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...
Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...
June 21, 2010 (UPDATED July 29, 2010) — The US Food and Drug Administration (FDA) has approved nilotinib (Tasigna, Novartis) as a first-line treatment of chronic-phase Philadelphia chromosome-positive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback